These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16900441)

  • 21. TRPV1 gene knockout impairs postischemic recovery in isolated perfused heart in mice.
    Wang L; Wang DH
    Circulation; 2005 Dec; 112(23):3617-23. PubMed ID: 16314376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist reverses endothelial dysfunction in diabetic (db/db-/-) mice.
    Howarth AG; Wiehler WB; Pannirselvam M; Jiang Y; Berger JP; Severson D; Anderson TJ; Triggle CR
    J Pharmacol Exp Ther; 2006 Jan; 316(1):364-70. PubMed ID: 16249369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
    Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelial nitric oxide contributes to the renal protective effects of ischemic preconditioning.
    Yamasowa H; Shimizu S; Inoue T; Takaoka M; Matsumura Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):153-9. PubMed ID: 15308652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coronary flow regulation in mouse heart during hypercapnic acidosis: role of NO and its compensation during eNOS impairment.
    Heintz A; Damm M; Brand M; Koch T; Deussen A
    Cardiovasc Res; 2008 Jan; 77(1):188-96. PubMed ID: 18006478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats.
    Sánchez-Hidalgo M; Martín AR; Villegas I; de la Lastra CA
    Eur J Pharmacol; 2007 May; 562(3):247-58. PubMed ID: 17343846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of ischaemic preconditioning in the eNOS overexpressed working mouse heart model.
    du Toit EF; Genade S; Carlini S; Moolman JA; Brunner F; Lochner A
    Eur J Pharmacol; 2007 Feb; 556(1-3):115-20. PubMed ID: 17157294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective modulation of endogenous nitric oxide formation in ischemia/reperfusion injury in isolated rat hearts--effects on regional myocardial flow and enzyme release.
    Han H; Kaiser R; Hu K; Laser M; Ertl G; Bauersachs J
    Basic Res Cardiol; 2003 May; 98(3):165-74. PubMed ID: 12883834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins.
    Tesse A; Al-Massarani G; Wangensteen R; Reitenbach S; Martínez MC; Andriantsitohaina R
    J Pharmacol Exp Ther; 2008 Feb; 324(2):539-47. PubMed ID: 18039959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
    Ihm SH; Chang K; Kim HY; Baek SH; Youn HJ; Seung KB; Kim JH
    Basic Res Cardiol; 2010 May; 105(3):399-407. PubMed ID: 19902320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling.
    Calvert JW; Gundewar S; Jha S; Greer JJ; Bestermann WH; Tian R; Lefer DJ
    Diabetes; 2008 Mar; 57(3):696-705. PubMed ID: 18083782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
    Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma.
    Cuzzocrea S; Mazzon E; Dugo L; Patel NS; Serraino I; Di Paola R; Genovese T; Britti D; De Maio M; Caputi AP; Thiemermann C
    Arthritis Rheum; 2003 Dec; 48(12):3544-56. PubMed ID: 14674008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
    Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
    Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardioprotective effect of an endothelin receptor antagonist during ischaemia/reperfusion in the severely atherosclerotic mouse heart.
    Gonon AT; Bulhak A; Bröijersén A; Pernow J
    Br J Pharmacol; 2005 Mar; 144(6):860-6. PubMed ID: 15685207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peroxisome proliferator-activated receptors gamma and alpha agonists stimulate cardiac glucose uptake via activation of AMP-activated protein kinase.
    Xiao X; Su G; Brown SN; Chen L; Ren J; Zhao P
    J Nutr Biochem; 2010 Jul; 21(7):621-6. PubMed ID: 19570670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms.
    Yi JH; Park SW; Brooks N; Lang BT; Vemuganti R
    Brain Res; 2008 Dec; 1244():164-72. PubMed ID: 18948087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PPARγ ligands regulate NADPH oxidase, eNOS, and barrier function in the lung following chronic alcohol ingestion.
    Wagner MC; Yeligar SM; Brown LA; Michael Hart C
    Alcohol Clin Exp Res; 2012 Feb; 36(2):197-206. PubMed ID: 21762184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adiponectin is required for PPARγ-mediated improvement of endothelial function in diabetic mice.
    Wong WT; Tian XY; Xu A; Yu J; Lau CW; Hoo RL; Wang Y; Lee VW; Lam KS; Vanhoutte PM; Huang Y
    Cell Metab; 2011 Jul; 14(1):104-15. PubMed ID: 21723508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.